3697-66-3 Usage
Description
1-(Ethoxycarbonyl)cyclopropanecarboxylic acid, also known as cyclopropanecarboxylic acid with an ethoxycarbonyl group, is an organic compound characterized by its unique cyclopropane ring structure and functional groups. It is a versatile molecule with potential applications in various industries due to its chemical properties and reactivity.
Uses
Used in Pharmaceutical Industry:
1-(Ethoxycarbonyl)cyclopropanecarboxylic acid is used as a key intermediate in the synthesis of broad-spectrum anticancer medicine cabozantinib. It plays a crucial role in the development of this medication, which targets multiple receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis, and metastasis, making it a valuable compound in the fight against various types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 3697-66-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,6,9 and 7 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 3697-66:
(6*3)+(5*6)+(4*9)+(3*7)+(2*6)+(1*6)=123
123 % 10 = 3
So 3697-66-3 is a valid CAS Registry Number.
3697-66-3Relevant articles and documents
Efficient method for removal of a carboxylic acid moiety from sterically crowded cyclopropanedicarboxylic acid derivatives
Hell, Zoltan,Toke, Laszlo
, p. 2127 - 2133 (1996)
A versatile method was developed to the dealkoxycarbonylation of sterically crowded cyclopropanecarboxylic acid derivatives via a nonhydrolytic ester cleavage followed by a Barton-type decarboxylation.
SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME
-
Paragraph 00318, (2019/03/17)
Provided herein are compounds and compositions useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
Paragraph 0380; 0381, (2018/03/25)
The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):